

# Erythropoietin attenuates hydrogen peroxide-induced damage of hepatocytes

Hepatositlerde oluşturulan hidrojen peroksit toksisitesinde eritropoietin'in koruyucu rolü

Nuray YAZIHAN<sup>1,2</sup>, Haluk ATAÖĞLU<sup>2,3</sup>, Burcu YENER<sup>2</sup>, Cengiz AYDIN<sup>4</sup>

Departments of <sup>1</sup>Pathophysiology and <sup>2</sup>Microbiology and <sup>3</sup>Molecular Biology Research and Development Unit, Ankara University, Faculty of Medicine, Ankara

<sup>4</sup>Clinical Biochemistry Laboratory, Yüksek İhtisas Research and Training Hospital, Ankara

**Background/aims:** High levels of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) are observed during inflammatory and ischemic states of the liver and usually lead to cellular dysfunction and cytotoxicity. Recently, it has been reported that erythropoietin and mitochondrial K (ATP) channel openers have a protective effect via a pharmacological preconditioning action during ischemia reperfusion injury of the liver and heart. However, it remains unclear as to whether K (ATP) channel blockers can reduce the protective effect of erythropoietin in the H<sub>2</sub>O<sub>2</sub>-induced injury of hepatocytes. **Methods:** To determine whether erythropoietin treatment decreases H<sub>2</sub>O<sub>2</sub>-induced toxicity, we used human hepatocyte cell line Hep3B for assays. Cells were pretreated with different dosages of erythropoietin (0.1-1-10-50 IU/ml) 2 h before H<sub>2</sub>O<sub>2</sub> application. For determination of effects of blockage of mitochondrial K (ATP) channels during erythropoietin treatment, glibenclamide treatment was applied to the medium 2 h before H<sub>2</sub>O<sub>2</sub> toxicity. Cell number, lactate dehydrogenase and caspase-3 levels were measured in erythropoietin, glibenclamide and/or H<sub>2</sub>O<sub>2</sub>-treated groups. **Results:** Erythropoietin treatment significantly increased cell number at the 24<sup>th</sup> and 48<sup>th</sup> h compared to the control group. H<sub>2</sub>O<sub>2</sub> application induced apoptosis and lactate dehydrogenase release from Hep3B cells and decreased cell number. Erythropoietin prevents H<sub>2</sub>O<sub>2</sub> toxicity in hepatocytes. The K channel inhibitor glibenclamide decreased the cytoproliferative and cytoprotective effect of erythropoietin during H<sub>2</sub>O<sub>2</sub> toxicity of Hep3B cells. **Conclusions:** Erythropoietin treatment may be considered as a therapeutic agent during oxidative injuries of hepatocytes and its cytoprotective effect is abolished by glibenclamide.

**Key words:** ATP dependent K channel, caspase-3, erythropoietin (EPO), glibenclamide, hepatocyte, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) toxicity, lactate dehydrogenase (LDH)

**Amaç:** Karaciğerin enflamatuvar ve iskemik hasarlarında yüksek düzeyde H<sub>2</sub>O<sub>2</sub> açığa çıkmakta ve genellikle hücresel disfonksiyona ve sitotoksositeye neden olmaktadır. Son dönemlerde, eritropoietin ve mitokondrial K (ATP) kanal açıcılarının karaciğer ve kalbin iskemi reperfüzyon hasarı sırasında farmakolojik önşartlanma oluşturarak koruyucu etkiye sahip olduğu gösterilmiştir. Bununla beraber; K (ATP) kanal blokörlerinin, eritropoietinin karaciğerde oluşturulan H<sub>2</sub>O<sub>2</sub> toksisitesine karşı koruyucu etkisini azaltıp azaltamayacağı henüz bilinmemektedir. **Yöntem:** Eritropoietinin H<sub>2</sub>O<sub>2</sub> ile oluşturulan toksisitesindeki etkisini araştırmak amacıyla çalışmamızda insan hepatosit hücre dizisi Hep3B kullanılmıştır. Hücreler H<sub>2</sub>O<sub>2</sub> uygulamasından 2 saat önce eritropoietinin farklı dozlarıyla (0.1-1-10-50 IU/ml) ön tedavi edilmiştir. Eritropoietinin uygulaması sırasında mitokondrial K (ATP) kanal blokajının etkisini görmek amacıyla glibenklamid ortama H<sub>2</sub>O<sub>2</sub> toksisitesinden 2 saat önce eritropoietin ile eşzamanlı olarak eklenmiştir. Hücre sayısı, laktat dehidrogenaz ve kaspaz-3 düzeyleri eritropoietin, glibenklamid ve/veya H<sub>2</sub>O<sub>2</sub> ile muamele edilmiş hücrelerde ölçülmüştür. **Bulgular:** Eritropoietin uygulaması hücre sayısını kontrol grubuna göre 24 ve 48. saatlerde belirgin bir şekilde arttırmıştır. H<sub>2</sub>O<sub>2</sub> eklenmesi; hücrelerde apoptosis, hücre ölümlü ve laktat dehidrogenaz salınımını arttırmıştır. Eritropoietinin tedavisi; hepatositleri H<sub>2</sub>O<sub>2</sub> toksisitesinden korumuştur. K kanal inhibitörü glibenklamid Hep3B lerde H<sub>2</sub>O<sub>2</sub> toksisitesi sırasındaki sitoproliferatif ve sitoprotektif etkisini azaltmıştır. **Sonuç:** Eritropoietin uygulaması hepatositlerin oksidatif hasarı sırasında törapetik bir ajan olarak önerilebilir ve eritropoietinin sitoprotektif etkisi glibenklamid ile azalmaktadır.

**Anahtar kelimeler:** ATP bağımlı K kanalı, kaspaz-3, eritropoietin (EPO), glibenklamid, hepatosit, hidrojen peroksit (H<sub>2</sub>O<sub>2</sub>) toksisitesi, laktat dehidrogenaz (LDH)

## INTRODUCTION

In liver injury, hepatocytes are subjected to oxidative stress from both reactive oxidative species (ROS) generated intracellularly in response to

cytokines and hepatotoxins and ROS produced extracellularly by inflammatory cells. Peroxisomal oxidases and microsomal cytochrome P450 enzy-

Address for correspondence: Nuray YAZIHAN

Department of Pathophysiology, Ankara University, Faculty of Medicine, Ankara, Turkey

Phone: +90 312 310 30 10-372 • Fax: +90 312 310 63 70

Manuscript received: 26.04.2007 Accepted: 13.09.2007

mes are the most important sources of ROS, jointly accounting for the production of 80% of the hydrogen peroxide ( $H_2O_2$ ) in the liver under normal physiological conditions (1). Both exogenously exposed and endogenously produced ROS are known to act as intermediates in apoptotic signaling.  $H_2O_2$  is involved in numerous types of cell and tissue injury. High levels of  $H_2O_2$  are observed during inflammatory states and usually lead to cellular dysfunction and cytotoxicity. Especially during alcohol-induced hepatotoxicity, induction of microsomal cytochrome *P*450 enzymes occurs (2). During infections and inflammation, neutrophils trigger a long-lasting oxidant stress through NADPH oxidase. Superoxide generated by NADPH oxidase dismutates to oxygen and  $H_2O_2$ , which is a highly diffusible oxidant. In addition, myeloperoxidase released from the neutrophils' azurophilic granules can generate hypochlorous acid (3). The hydroxyl and superoxide radicals generated by  $H_2O_2$  can lead to necrotic cell injury through damaging interactions with cellular DNA, protein, or lipids, which disrupts critical cellular macromolecules and energy production (1,4).

Erythropoietin (EPO) is a hematopoietic cytokine. Decreased oxygen delivery, most often due to anemic hypoxemia, is the primary stimulus to EPO release. Typical for cytokines, EPO has multiple functions besides bone marrow. Previous studies showed that it has strong antiapoptotic and antioxidant properties (5,6). EPO activates different protein kinase signalling pathways and can increase resistance to ischemia and oxidative stress. Before ischemia reperfusion (I/R) injuries, administration of mitochondrial ATP dependent K channel opener protects neurons from oxidative damage and apoptosis (7,8). The same results were seen after a liver I/R model (9). EPO treatment during I/R damage mimics preconditioning (10). It has been shown that ATP dependent K channel activation is involved in cardioprotective effects of EPO during cardiac I/R damage (11). Previous studies demonstrated the sizeable beneficial effects of EPO in several clinical *in vivo* models of I/R injury (9), shock (12) and laparoscopy (10) induced damage of the liver, but direct effect of EPO treatment during  $H_2O_2$  toxicity in hepatocytes is not yet known. In this study, we aimed to investigate whether EPO treatment is protective during  $H_2O_2$  toxicity and its relationship with ATP dependent K channel activation.

## MATERIALS AND METHODS

### Cell lines, chemicals and materials:

Human hepatoma cell line Hep3B cells were obtained from the ATCC. Cells were cultured in RPMI-1640 medium (PAA, Austria), supplemented with fetal calf serum (FCS) (PAA, Austria), L-glutamine (Sigma, USA), streptomycin (Sigma, USA) and penicillin (Sigma, USA). Effect of EPO (rHuEPO – recombinant human erythropoietin- Eprex 4000 IU/0.4 ml flacon, Janssen-Cilag) treatment during  $H_2O_2$  (Sigma, USA) toxicity was studied. Cell counts were tested by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT, Sigma, USA). For evaluation of apoptosis, caspase-3 levels were measured by a fluorometric kit (Biotium, USA). Lactate dehydrogenase (LDH) level was measured with a kit using an automatic multianalyzer (Roche; P800).

Effects of glibenclamide (Sigma, USA) during  $H_2O_2$  toxicity were evaluated.

### Cell culture and experimental protocol:

The human hepatoma cell line Hep3B was cultured in RPMI-1640 medium, supplemented with 10% v/v FCS, 2 mM L-glutamine, streptomycin (100  $\mu$ g/ml) and penicillin (100 IU/ml) in a humidified atmosphere containing 5%  $CO_2$  at 37°C. One day before the experiments, cells were seeded on 96-well microtiter plates (Nunc, Denmark) as  $2 \times 10^5$  cells/ml.

Depending on the groups, different concentrations of EPO (0.1-1-10-50 IU/ml), glibenclamide (10  $\mu$ M) and/or  $H_2O_2$  (100  $\mu$ M) were added to medium. Before induction of cell death by  $H_2O_2$ , cells were pretreated with different dosages of EPO for 2 h, then  $H_2O_2$  was applied for 2 h. Then medium was changed according to group protocols. Glibenclamide treatment was applied to medium 2 h before  $H_2O_2$  toxicity. For determination of effects of glibenclamide during EPO treatment, we used EPO at a concentration of 50 IU/ml in the experiment.

LDH and caspase-3 levels were measured from EPO, glibenclamide and/or  $H_2O_2$  treated groups at the 48<sup>th</sup> h. After supernatants were removed, cell surface was washed with sterile phosphate buffered saline (PBS) and cells were harvested with lysis solution, and caspase-3 levels of groups were measured from cell lysates. LDH measurement was done from both the supernatant and cell lysate.

### Evaluation of cellular proliferation:

The MTT, a colorimetric assay based upon the ability of living cells to reduce 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide into formazan, was used for evaluation of the effects of H<sub>2</sub>O<sub>2</sub>, EPO and glibenclamide on cellular death or proliferation (2<sup>nd</sup>, 24<sup>th</sup> and 48<sup>th</sup> h).

### Biochemical Determination of Cell Death

Hep3B cells were plated in 96 multi-well culture plates as 3X10<sup>5</sup> cells/ml. LDH is normally present in the cytosol of hepatocytes. In response to cell damage, LDH is released from the cells. Therefore, to determine cell death, we measured secreted and intracellular LDH levels and we calculated % released LDH at the 48<sup>th</sup> h of each group. To do this, the medium was collected to measure enzyme activities. The adherent cells were lysed. Both medium and cell lysates were used for quantitative determination of LDH activity (IU/L), which was performed with an automatic multianalyzer (Roche) using kit (Roche). Released enzyme fractions for each sample were calculated as the ratio of enzyme present in the medium vs. the sum of the levels of the same enzyme in the supernatant and in the cells.

### Measurement of apoptosis:

#### Caspase-3 levels:

The presence of apoptosis was determined by caspase-3 levels. Equal numbers of cells were used for caspase-3 level measurements. Cells were lysed with assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10 mM DTT, 2 mM EDTA, 2 mM EGTA, Triton X-100, 0.1%). Caspase-3 levels were measured by DEVD-R110 Fluorometric HTS Assay Kit from cell lysates. The fluorogenic substrate (Ac-DEVD)<sub>2</sub>-R110 was used for this assay. It is completely hydrolyzed by the enzyme in two successive steps. Cleavage of the first DEVD peptide results in the monopeptide Ac-DEVD-R110 intermediate, which has absorption and emission wavelengths similar to those of R110 ( $\lambda_{\text{abs}}/\lambda_{\text{abs}}=496/520$  nm), but has only about 10% the fluorescence of the latter. Hydrolysis of the second DEVD peptide releases the dye R110, leading to a substantial fluorescence increase.

Equal volumes of sample and caspase-3 detection buffer were added to assay plate, then incubated at 37°C for 1 h. Results were read with a fluorometer at 470 nm excitation filter and 520 nm emissi-

on filter. R110 was used for generating a standard curve to calculate amount of substrate conversion.


### Statistical Analysis

Results of the experiments were analyzed by one way ANOVA, followed by a multiple comparison test using SPSS 10.0.  $p < 0.05$  was accepted as statistically significant. Results are given as mean  $\pm$  SEM.

## RESULTS

### Cell proliferation and toxicity:

H<sub>2</sub>O<sub>2</sub> exposure decreased living cell number immediately at the 2<sup>nd</sup> h compared to control and EPO treatment groups ( $p < 0.05$ ). At the end of the experiment (48<sup>th</sup> h), cell numbers in the H<sub>2</sub>O<sub>2</sub>-treated group were decreased significantly compared to the other groups ( $p < 0.001$ ). At the 48<sup>th</sup> h of EPO treatment, hepatocyte number was increased compared to H<sub>2</sub>O<sub>2</sub> and control groups ( $p < 0.001$ ). There was no significant difference between cytoprotective effects of the different dosages of EPO treatment during H<sub>2</sub>O<sub>2</sub> toxicity (Figure 1).




**Figure 1.** % Cell death was determined at 2<sup>nd</sup>, 24<sup>th</sup> and 48<sup>th</sup> h by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. H<sub>2</sub>O<sub>2</sub> exposure induced prominent cell death in Hep3B hepatocytes. Data are from six independent experiments for each condition. Data are given as mean  $\pm$  SEM.  $P < 0.05$  was accepted as statistically significant.

<sup>a</sup>represents  $p < 0.05$ , <sup>b</sup>represents  $p < 0.001$  difference between H<sub>2</sub>O<sub>2</sub>-exposed cells and the control group.

Glibenclamide diminished the proliferative and cytoprotective effect of EPO treatment ( $p < 0.05$ ) (Figure 2).

Cellular cytotoxicity of H<sub>2</sub>O<sub>2</sub> was also determined by LDH release percentages at the 48<sup>th</sup> h. H<sub>2</sub>O<sub>2</sub> ex-




**Figure 2.** ATP dependent K channel blockage with glibenclamide inhibited the cytoproliferative effect of EPO. Data are given as mean±SEM.  $P < 0.05$  was accepted as statistically significant. <sup>a</sup>represents  $p < 0.05$ , <sup>b</sup>represents  $p < 0.001$  difference between H<sub>2</sub>O<sub>2</sub>-exposed cells and the control group.


posure caused increased LDH release from Hep3B cells. EPO treatment protected hepatocytes from toxic effects of H<sub>2</sub>O<sub>2</sub> (Figure 3).

#### Determination of apoptosis:


Caspase-3 level was used for the determination of the apoptotic effect of H<sub>2</sub>O<sub>2</sub>. At the 48<sup>th</sup> h, H<sub>2</sub>O<sub>2</sub> caused apoptosis in Hep3B cells ( $p < 0.001$ ). EPO treatment was protective against H<sub>2</sub>O<sub>2</sub> by decreasing apoptosis as measured by caspase-3 levels (Figure 4). Similar results were seen from the apoptosis assay like MTT and LDH leakage. Glibenclamide abolished the antiapoptotic effect of EPO treatment at the 48<sup>th</sup> h. Glibenclamide alone slightly increased apoptosis in Hep3B cells but it was not statistically significant (Figure 5).



**Figure 3.** H<sub>2</sub>O<sub>2</sub> induced cytotoxicity at the 48<sup>th</sup> h of the experiment determined by LDH % released to medium. H<sub>2</sub>O<sub>2</sub> induced two-fold LDH release from hepatocytes at the end of the 48<sup>th</sup> h ( $p < 0.01$ ). Data are given as mean±SEM. <sup>\*</sup>represents difference between control and H<sub>2</sub>O<sub>2</sub> groups.



**Figure 4.** Caspase-3 levels: H<sub>2</sub>O<sub>2</sub> toxicity caused prominent apoptosis at the 48<sup>th</sup> h ( $p < 0.001$ ). EPO treatment during H<sub>2</sub>O<sub>2</sub> toxicity decreased apoptosis. Data are given as mean±SEM. <sup>\*</sup>represents difference between control and H<sub>2</sub>O<sub>2</sub> toxicity groups ( $p < 0.001$ ).



**Figure 5.** Caspase-3 levels: Glibenclamide, EPO, EPO+glibenclamide treatment did not cause any increase in caspase-3 levels of the hepatocytes at the 48<sup>th</sup> h. H<sub>2</sub>O<sub>2</sub> toxicity increased caspase-3 levels compared to control ( $p < 0.001$ ). EPO treatment during toxicity decreased H<sub>2</sub>O<sub>2</sub>-induced damage ( $p < 0.01$ ). <sup>a</sup>represents difference between H<sub>2</sub>O<sub>2</sub>, glibenclamide-H<sub>2</sub>O<sub>2</sub> and control groups ( $p < 0.001$ ). <sup>b</sup>represents difference between EPO-glibenclamide-H<sub>2</sub>O<sub>2</sub> and control groups ( $p < 0.01$ ).

## DISCUSSION

In liver diseases, ROS are involved in cell death and liver injury. During oxidative stress or ischemia, mitochondrial damage occurs; cytochrome c releases and activates downstream caspases leading to apoptosis. Application of H<sub>2</sub>O<sub>2</sub> induced apoptosis and cell death in hepatocytes (1). We found increased caspase-3 level in this group. LDH is an enzyme that is normally present in the cytosol of hepatocytes. In response to cell damage (necrosis or late-stage apoptosis), LDH is released from the cells (13). Therefore, to determine cell death, we measured secreted and intracellular LDH



levels. Cell number of the H<sub>2</sub>O<sub>2</sub> toxicity group was lower at the 48<sup>th</sup> h compared to 2<sup>nd</sup> and 24<sup>th</sup> h. We calculated % released LDH at the 48<sup>th</sup> h of each group. As a result of increased cellular damage, increased LDH leakage occurs from cells to the medium, as we found in the H<sub>2</sub>O<sub>2</sub> toxicity group.

We applied EPO treatment before H<sub>2</sub>O<sub>2</sub> toxicity. Application of EPO decreased peroxide-triggered apoptosis, LDH leakage, and cell death. Caspase-3 levels were decreased in the EPO treatment group. We found that EPO treatment has antiapoptotic and proliferative effect on hepatocytes, and this effect was independent of the dosages selected in the experimental design. EPO had a hepatoprotective effect against H<sub>2</sub>O<sub>2</sub> toxicity and the nonspecific ATP dependent K channel blocker, glibenclamide, abolished this effect. Direct acute protective effects of EPO have been shown to implicate these channels. Previous studies have shown that systemic application of single-dose EPO treatment inhibits nitric oxide mediated free-radical formation in the rat liver, and reduces oxidative stress, caspase-3 levels and liver enzymes in the serum of rats after I/R injury (9-12). Our study supported these findings and we found that EPO has a direct cytoprotective and cytoproliferative effect on hepatocytes.

Information related to the role of K channels in hepatocytes is limited. The ATP-sensitive K<sup>+</sup> channels in both sarcolemmal and mitochondrial inner membrane are the critical mediators in cellular protection of ischemic preconditioning. Activation of mitochondrial ATP dependent K<sup>+</sup> channels plays a significant role in the reduction of

apoptosis (13,14). ATP dependent K<sup>+</sup> channels have significant roles in liver growth control as indicated by stimulation of DNA synthesis. It was shown that K ATP channel blockers quinidine and glibenclamide inhibited DNA synthesis both with and without hepatic growth factor stimulation in hepatocytes (15).

Opening of these channels has been related to protein kinase C activation, calcium-mediated signals and through mitogen-activated protein kinases (MAPK) activation (16,17). It is known that EPO activates protein kinase receptors and MAPK. Activation of protein kinases induces mitogenic activity in cells (18). The cytoproliferative effect of EPO is also mediated by these kinases and these effects were blocked by ATP dependent K channel blockage (19). Although we did not evaluate intracellular pathways and kinases, blockage of the cytoprotective and proliferative effects of EPO treatment by K channel blockage might be due to blockage of protein kinases.

In conclusion, these results suggest that the protective role of EPO against hepatic H<sub>2</sub>O<sub>2</sub> toxicity correlated with activation of ATP dependent K channel activation.

EPO is a therapeutic drug for different liver injury models. However, further investigations are required to clarify this role, because the hepatic protective mechanisms associated with EPO and subtypes of K ATP channels are not yet clearly defined.

### Acknowledgement

This study was supported by TUBITAK - project no: SBAG-2812-104S32.

### REFERENCES

1. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. *Toxicol Sci* 2002; 65(2): 166-76.
2. Yeldandi AV, Rao MS, Reddy JK. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. *Mutat Res* 2000; 448(2): 159-77.
3. Jaeschke H. Mechanisms of liver injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. *Am J Physiol Gastrointest Liver Physiol* 2006; 290(6): G1083-8.
4. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. *Am J Physiol Gastrointest Liver Physiol* 2006; 290(4): G583-9.
5. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. *Cell Death Differ* 2004; 11 (Suppl 1): S37-44.
6. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia correction. *Pediatr Nephrol* 2006; 21(12): 1785-9.
7. Wei L, Yu SP, Gottron F, et al. Potassium channel blockers attenuate hypoxia- and ischemia-induced neuronal death in vitro and in vivo. *Stroke* 2003; 34(5): 1281-6.
8. Chai Y, Niu L, Sun XL, et al. Iptakalim protects PC12 cell against H<sub>2</sub>O<sub>2</sub>-induced oxidative injury via opening mitochondrial ATP-sensitive potassium channel. *Biochem Biophys Res Commun* 2006; 350(2): 307-14.
9. Hai S, Takemura S, Minamiyama Y, et al. Mitochondrial K(ATP) channel opener prevents ischemia-reperfusion injury in rat liver. *Transplant Proc* 2005; 37(1): 428-31.
10. Ates E, Yilmaz S, Ihtiyar E, et al. Preconditioning-like amelioration of erythropoietin against laparoscopy-induced oxidative injury. *Surg Endosc* 2006; 20(5): 815-9.
11. Joyeux-Faure M, Ramond A, Beguin PC, et al. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. *Fundam Clin Pharmacol* 2006; 20(1): 51-6.

12. Cuzzocrea S, Di Paola R, Mazzon E, et al. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. *Crit Care Med.* 2006; 34(4): 1168-77.
13. Peltenburg HG, Hermens WT, Willems GM, et al. Estimation of the fractional catabolic rate constants for the elimination of cytosolic liver enzymes from plasma. *Hepatology* 1989; 10(5): 833-9.
14. Liu D, Slevin JR, Lu C, et al. Involvement of mitochondrial K<sup>+</sup> release and cellular efflux in ischemic and apoptotic neuronal death. *J Neurochem* 2003; 86(4): 966-79.
15. Takashi E, Wang Y, Ashraf M. Activation of mitochondrial K(ATP) channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway. *Circ Res* 1999; 85(12): 1146-53.
16. Malhi H, Irani AN, Rajvanshi P, et al. KATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. *J Biol Chem* 2000; 275(34): 26050-7.
17. Huang Q, Bu S, Yu Y, et al. Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax ratio and p38-beta mitogen-activated protein kinase. *Endocrinology* 2007; 148(1): 81-91.
18. Ahmad N, Wang Y, Haider KH, et al. Cardiac protection by mitoKATP channels is dependent on Akt translocation from cytosol to mitochondria during late preconditioning. *Am J Physiol Heart Circ Physiol* 2006; 290(6): H2402-8.
19. Hanlon PR, Fu P, Wright GL, et al. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. *FASEB J* 2005; 19(10): 1323-5.